Biocept, Inc. (NASDAQ:BIOC) announced its earnings results on Thursday. The medical research company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.01, Morningstar.com reports. Biocept had a negative net margin of 383.29% and a negative return on equity of 1,177.51%. The business had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.23 million.

Biocept (NASDAQ:BIOC) traded down 13.73% during trading on Friday, reaching $1.25. The company had a trading volume of 777,933 shares. The firm’s market capitalization is $33.25 million. Biocept has a 12-month low of $0.74 and a 12-month high of $3.39. The firm’s 50 day moving average price is $1.40 and its 200 day moving average price is $1.68.

A number of institutional investors have recently modified their holdings of BIOC. Intellectus Partners LLC boosted its position in shares of Biocept by 6,250.0% in the first quarter. Intellectus Partners LLC now owns 127,000 shares of the medical research company’s stock worth $271,000 after buying an additional 125,000 shares during the last quarter. WealthTrust Axiom LLC purchased a new position in shares of Biocept during the first quarter worth about $298,000. Creative Planning boosted its position in shares of Biocept by 64,679.8% in the second quarter. Creative Planning now owns 246,811 shares of the medical research company’s stock worth $338,000 after buying an additional 246,430 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Biocept by 9.6% in the second quarter. Vanguard Group Inc. now owns 764,351 shares of the medical research company’s stock worth $1,048,000 after buying an additional 66,746 shares during the last quarter. 15.26% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on the company. Westpark Capital restated an “outperform” rating on shares of Biocept in a research note on Thursday, August 3rd. Zacks Investment Research lowered Biocept from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, ValuEngine upgraded Biocept from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Biocept currently has an average rating of “Buy” and a consensus target price of $2.31.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/biocept-inc-nasdaqbioc-posts-earnings-results-misses-expectations-by-0-01-eps.html.

Biocept Company Profile

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Earnings History for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.